Lipocine Inc.

LPCN

Healthcare|Biotechnology|US

$1.57

+0.04 (+2.61%)

DCF Value

$0.67

Tangible Book / Share

$2.57

Cash / Share

$2.60

Clinical Trials (9)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT07822321 Brexanolone Lifting Outcomes Of Moms	Depression, Postpartum, Postpartum Depression (PPD)	P3	Recruiting	120	RCT, Double-blind	LPCN 1154A, Placebo
NCT03242590 Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).	Hypogonadism, Male	P3	Completed	95	Open-label	LPCN 1021
NCT03868059 Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men	Hypogonadism, Male	P3	Completed	138	Open-label	LPCN 1021
NCT03242408 Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)	Hypogonadism, Male	P3	Completed	100	Open-label	LPCN 1021
NCT02081300 Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism	Male Hypogonadism	P3	Completed	315	RCT, Open-label	Oral testosterone undecanoate, LPCN 1021, Topical testosterone gel 1.62 %
NCT06979544 A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD	Depression, Postpartum, Depression, Post-Partum	P3	Completed	90	RCT, Double-blind	LPCN 1154A, Placebo
NCT04134091 The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis	Nonalcoholic Steatohepatitis (NASH)	P2	Completed	56	RCT, Double-blind	LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo
NCT04874350 A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia	Liver Cirrhosis, Sarcopenia	P2	Completed	30	RCT, Double-blind	LPCN 1148, Placebo
NCT04685993 A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial	NASH - Nonalcoholic Steatohepatitis	P2	Completed	25	Open-label	LPCN 1144